



## Clinical Guideline

# Care of the well child, newly diagnosed with Type 1 Diabetes Mellitus

<b>SETTING</b>	<i>Insert hospital name</i>
<b>FOR STAFF</b>	Medical and nursing staff
<b>PATIENTS</b>	Children with diabetes and their families

### Patient group

This guideline is intended for use in managing children presenting with newly diagnosed diabetes who are well, not acidotic, not significantly dehydrated and able to tolerate oral rehydration

### Exclusion criteria

This guideline does not cover the management of children presenting in moderate or severe diabetic ketoacidosis (DKA). For children presenting in DKA the current national guideline for management of children presenting in diabetic ketoacidosis should be followed<sup>1</sup>

### Diagnostic Criteria for Diabetes Mellitus in Childhood and Adolescence

WHO Diagnostic criteria for diabetes based on blood glucose measurements **and** the presence or absence of symptoms as detailed below<sup>2</sup>.

1. Symptoms of diabetes plus casual plasma glucose concentration  $\geq 11.1$  mmol/L (200 mg/dl)\*.  
Casual is defined as any time of day without regard to time since last meal.  
**or**
2. Fasting plasma glucose  $\geq 7.0$  mmol/l ( $\geq 126$  mg/dl).<sup>†</sup>  
Fasting is defined as no caloric intake for at least 8 h.  
**or**
3. 2-hour postload glucose  $\geq 11.1$  mmol/l ( $\geq 200$  mg/dl) during an OGTT.  
The test should be performed as described by WHO (86), using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water or 1.75 g/kg of body weight to a maximum of 75 g (65).

\*Corresponding values (mmol/L) are  $\geq 10.0$  for venous whole blood and  $\geq 11.1$  for capillary whole blood and  
<sup>†</sup> $\geq 6.3$  for both venous and capillary whole blood

### Investigations to perform at diagnosis

- **Random blood glucose**
- **HbA1c (glycated haemoglobin)**
- **Screening for coeliac disease:** Measure either IgA anti tissue transglutaminase antibodies (tTGA) or IgA anti-endomysial antibody (EMA). There is no evidence to support use of both. Do not carry out anti-gliadin antibody serological tests<sup>5, 6, 7</sup>.



## Association of Children's Diabetes Clinicians

- Measure total IgA
  - The IgA tTGA and IgA EMA serological tests show high levels of sensitivity and specificity in the diagnostic process for coeliac disease if IgA sufficient.
  - Anti-gliadin antibody serological tests show lower levels of sensitivity and specificity than tTGA and EMA.
  - If IgA deficient then use IgGtTGA or EMA as a screening test.
- **Screening for thyroid disease** – Measure both thyroid function tests (TSH) and Thyroid Peroxidase antibodies (TPO).
    - Literature suggests that between 4.2% and 9.6% of individuals will develop thyroid disease – with 39% developing it within 1 year of diagnosis<sup>8-11</sup>
  - **Cataract:** Eye screening via simple fundoscopy is appropriate
    - Approximately 0.7% of children presenting with diabetes have a cataract secondary to metabolic disturbance<sup>12</sup>.
  - **Antibody markers predicting type 1 diabetes:** NICE advises against using Islet Cell Antibodies (ICA) and Glutamic Acid Decarboxylase Autoantibodies (GAD antibodies) to distinguish between Type 1 and other forms of diabetes, but they may be helpful as part of an overall clinical picture.
    - Antibody negative diabetes is not unusual. Reports suggest somewhere between 20 to 30% of children may be antibody negative at diagnosis<sup>3,4</sup>. Islet cell antibodies are more likely to be positive with studies reporting them positive in approximately 80% of children with diabetes<sup>3</sup>. There is significant variation though with age. In children diagnosed under the age of five approximately 10% are antibody negative. At 17yrs this increases to 44%<sup>3</sup> Alternative types of diabetes to type 1 should be considered if the patient is antibody negative and has a strong family history of diabetes.
  - **C peptide:** This can be difficult to interpret, but may be useful where diagnosis of type of diabetes is unclear or for research purposes. C-peptide concentrations have better discriminative value the longer the interval between presentation and testing.
  - **Genetics:** Consider genetic testing if clinical features, disease behaviour or family history suggests monogenic diabetes<sup>16</sup>.

### What insulin regimen should be started at diagnosis?

- **Children are likely to benefit from an intensive insulin regimen and support at diagnosis** (either multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII)). However due consideration needs to be given to patient and caregiver preferences.
- For those children / young people starting on multiple daily injections approximately 50% of the total daily dose should be basal insulin analogue (such as insulin glargine, insulin detemir or insulin degludec) and 50% given as rapid insulin analogue (e.g. Insulin Aspart, insulin Lispro, insulin Glulisine) in 3 divided doses before meals.
- Families should be taught **level 3** carbohydrate counting soon after diagnosis<sup>16</sup>.
- For those children requiring conventional mixed insulin regimen (e.g. twice daily Novomix 30 or Humalog mix 25) the total daily dose is the same but two thirds of the total daily dose needs to be



## Association of Children's Diabetes Clinicians

given before breakfast and one third before the evening meal. The range of premixed insulin currently available is limited.

- The Diabetes Control and Complication Trial demonstrated that adolescents and adults with type 1 diabetes managed with intensive insulin therapy and support achieved better control when compared to those on conventional insulin therapy<sup>13</sup>
- SEARCH for Diabetes In Youth Study Group examined the impact of insulin regimen intensification on metabolic outcomes (over time) in 1,606 children and young people with type 1 diabetes who had a baseline visit and at least one follow-up. Insulin regimens were divided into five categories. Category 1 (basal-bolus insulin with CSII) was considered the most intensive and category 5 (1-2 insulin injections per day, excluding basal insulin glargine or detemir) was considered the least intensive. Between baseline and most recent follow-up visit, 51.7% of the participants changed to a more intensive regimen, 44.7% had no change in their regimen, and 3.6% changed to a less intensive regimen. Among the youth in the no-change group, 15% were already on CSII at their baseline visit, and 56% were in either insulin regimen category 1 or 2 at baseline, indicating an intensive regimen at baseline. Over time, A1c levels increased significantly in all groups, but A1c levels were significantly lower in the more-intensive group than in the no-change group at the 1-year and 2-year visits ( $p < 0.05$ ). And both these groups showed a smaller increase in A1c than did the less-intensive group<sup>14</sup>.

### What dose of insulin should be used at diagnosis?

- The starting dose of insulin should be 0.5-0.75 units / kg / day. Adolescents and children with high levels of ketosis at diagnosis are likely to need doses at the higher end of this treatment range.
- Encourage patients to adjust their insulin doses based on general trends in their blood glucose levels and support them to do this<sup>16</sup>.

### How often should the blood glucose levels be checked?

Self-monitoring of blood glucose (SMBG) is essential to aid adjustment of insulin dosages. Advise the family to test blood glucose a **minimum of 5 times a day** (including before breakfast, lunch, supper and bed time)<sup>16</sup>.

- One systematic review identified poor quality studies which assessed the effect of frequency of self-monitoring on glycaemic control in people with type 1 diabetes. One non-randomised trial in children and two observational studies in adults reported that more frequent blood glucose monitoring ( $\geq 3$  tests per day) was associated with improvements in glycaemic control<sup>15</sup>
- **Target blood glucose (BG) levels:**
  - between 4 - 7mmol/L before meals<sup>16</sup>,
  - between 5-9 mmol/L post prandial 2 hours after meal<sup>16</sup>
  - 4-7 mmol/L at waking
  - $>5$  mmol/L for driving
  - The ideal target blood glucose for each child may vary with age and stage of puberty. The aim is to achieve blood glucose levels as close to normal as possible whilst avoiding frequent or severe hypoglycaemia.



### Ketone testing

- All children with diabetes need to be taught how to test for **blood ketones** as part of sick day rule advice and be provided with an appropriate ketone meter and testing strips<sup>16</sup>.
  - There are two methods of monitoring ketone bodies; the measurement of beta-hydroxybutyric acid by capillary blood sample and measurement of acetoacetic acid by urine dipstick test. In a two centre randomised controlled trial (RCT) of low risk of bias, including 123 children, adolescents and young adults aged under 22 years, use of blood ketone monitoring resulted in a significant reduction (of about 50%) in the incidence of hospitalisation or emergency assessment<sup>17</sup>.

### Inpatient or outpatient care?

- Both home based (or ambulatory care) and in patient care are safe.
- The decision to offer either should be based on availability of well trained staff to offer safe home based care, time of presentation, individual family circumstances and parental choice.
  - A Cochrane review concluded that there is insufficient high quality data to answer the question whether outpatient and /or home based management is better than in patient care<sup>18,19</sup>

### What structured Education topics should be covered at Diagnosis and during the first month following diagnosis?

TOPIC	DATE	DATE	DATE	DATE
<b>What is Diabetes?</b>				
Causes				
Symptoms				
Explanation of Honeymoon Period				
<b>Insulin</b>				
Different types of insulin, action & duration of action				
Dosages				
Use of correction doses				
Storage				
Leaflets				
<b>Injections</b>				
Technique				
Sites/rotation				
Pen/pump device				
Disposal of sharps				
<b>Blood Glucose Monitoring</b>				
Why we test				
How often & when				
Normal range				
When & how to seek advice				
Effect of diet, physical activity and illness on BG				



<b>Ketone testing</b>				
Why, how and when to test				
Interpretation of results and actions to take				
When & how to seek advice				
<b>Hypoglycaemia</b>				
What is hypoglycaemia				
Causes/symptoms/prevention				
Management including use of glucose tablets, Glucagon etc.				
<b>Dietary advice</b>				
Healthy eating				
Carbohydrate counting				
<b>Illness Management</b>				
Sick day rules and Diabetic Ketoacidosis prevention				
24hr Telephone contact numbers				
<b>Exercise</b>				
Encouragement of exercise				
Management of exercise with diabetes				
<b>Prescriptions</b> – what is available on the NHS				
<b>Identification</b>				
Medic alert / diabetes card				
<b>Disability Living allowance</b>				
<b>Managing at home and school</b>				
<b>School</b>				
School care plan				
Equipment for school including hypoglycaemia treatment				
<b>Support services</b> including Diabetes UK and JDRF				

Education and written information should be taken into account of the patient's and family/carer's learning needs and language preferences. Emotional and psychological support should be offered after diagnosis to patients and their family/carers<sup>16</sup>.

### What follow up should the child have after initiation of insulin therapy?

- On discharge, the family should be offered daily contact (face to face, telephone, text, email or 2 way telecommunication systems using video computer technology) with Diabetes Specialist Team for first 7 days following diagnosis.
- All children with diabetes mellitus should have access to 24 hour telephone advice
- All school aged children should have a school care plan in place either before or soon after return to school
  - Families, children and young people with diabetes benefit greatly from a good start to diabetes care pathway with confident, clear, positive messages, support and advice. Frequent contact with the children's diabetes team is recommended to help manage the changing requirements of diabetes in its early phases. The contacts may be in clinic, home visits or telephone<sup>19, 20</sup>.



## References

1. British Society for Paediatric Endocrinology and Diabetes (BSPED) guidelines for the management of DKA. <http://www.bsped.org.uk/professional/guidelines/docs/DKAGuideline.pdf>
2. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Report of WHO/IDF Consultation 2006.
3. Wang J, Miao D, Babu S, Yu J, Barker J, Klingensmith G et al. Prevalence of Autoantibody-Negative Diabetes Is Not Rare at All Ages and Increases with Older Age and Obesity. *Journal of Clinical Endocrinology & Metabolism* 2007;92:88-92.
4. Sabbah E, Savola K, Ebeling T, Kulmala P, Vähönsalo P, Ilonen J et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. *Diabetes Care* 2000;23:1326-32.
5. National Institute for Health and Clinical Excellence (NICE). Coeliac disease - Recognition and assessment of coeliac disease. Clinical Guideline 86. London: National Institute for Health and Clinical Excellence, 2009.
6. Baudon JJ, Johanet C, Absalon YB, Morgant G, Cabrol S, Mougenot JF. Diagnosing celiac disease: a comparison of human tissue transglutaminase antibodies with antigliadin and antiendomysium antibodies. *Arch.Pediatr.Adolesc.Med.* 2004;158:584-8.
7. Brusca I, Carroccio A, Tonutti E, Villalta D, Tozzoli R, Barrale M et al. The old and new tests for celiac disease: which is the best test combination to diagnose celiac disease in pediatric patients? *Clin.Chem.Lab Med.* 2011.
8. Bilimoria KY, Pescovitz OH, DiMeglio LA. Autoimmune thyroid dysfunction in children with type 1 diabetes mellitus: screening guidelines based on a retrospective analysis. *J.Pediatr.Endocrinol.Metab.* 2003;16:1111-7.
9. Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. *Arch.Dis.Child.* 2005;90:411-4.
10. Kordonouri O, Klinghammer A, Lang EB, Gruters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. *Diabetes Care.* 2002;25:1346-50.
11. Mantovani RM, Mantovani LM, Dias VM. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus: prevalence and risk factors. *J.Pediatr.Endocrinol.Metab.* 2007;20:669-75.
12. Iafusco D, Prisco F, Romano MR, Dell'omo R, Libondi T, Costagliola C. Acute juvenile cataract in newly diagnosed type 1 diabetic patients: a description of six cases. *Pediatr.Diabetes.* 2011;12:642-8.
13. The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 329 (14): 977-86.
14. Catherine Pihoker, Angela Badaru, Andrea Anderson, et al and for the SEARCH for Diabetes in Youth Study Group. Insulin Regimens and Clinical Outcomes in a Type 1 Diabetes Cohort: The SEARCH for Diabetes in Youth study *Diabetes Care* published ahead of print September 6, 2012, doi:10.2337/dc12-0720
15. Canadian Agency for Drugs and Technologies in Health. Systematic review of use of blood glucose test strips for the management of diabetes mellitus. [June 2010]. Available from [www.cadth.ca/products/cadth-overviews/vol-1.../vol-1-issue-1-01](http://www.cadth.ca/products/cadth-overviews/vol-1.../vol-1-issue-1-01)



## Association of Children's Diabetes Clinicians

16. NICE (2020) Diabetes (type 1 and type 2) in children and young people. NICE guideline NG18 [www.nice.org.uk/guidance/ng18](http://www.nice.org.uk/guidance/ng18)
17. Laffel LMB, Wentzell K, Loughlin C, Tovar A, Moltz K and Brink S (2006). Sick day management using 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: A randomised clinical trial, *Diabetic Medicine*; 23(3):278-284
18. Clar C, Waugh N, Thomas S. Routine Hospital admissions versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus. *Cochrane Database of systematic reviews* 2007, issue 2. Art No: CD004099. DOI: 10.1002/14651858.CD004099.pub 2
19. Home based care improved glycaemic control and was cost effective in children with type 1 diabetes. Dougherty G, Schriffin A, White D, et al. *Pediatrics* 1999 Jan; 103: 122-8.
20. The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pihoker C, Forsander G, Wolfsdorf J, Klingensmith GJ. *Pediatric diabetes* 2009; 10 (Suppl.12): 58-70